Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 126 Matches

Cetirizine_V14R1_AstraZeneca_20200327

Model Files Publication

Cetirizine for pediatric predictions.

Search Score: 2

Cycloguanil

Model Files Publication

Brand Name(s) include: N/A

Disease: Malaria

Drug Class: Antimalarials

Date Updated: March 2022

Related drugs: Proguanil

The model at-a-glance

Absorption Model	First-Order
Volume of Distribution	Full PBPK (Method 2)
Route of Elimination	Formed by CYP2C19, CYP3A4; unknown clearance mechanism
Perpetrator DDI	CYP2D6 Inhibitor
Validation	Proguanil and cycloguanil files were built using in vitro and clinical (Jeppersen et al., 1997) data 5 clinical studies describing single and multiple dose exposure of cycloguanil were used to verify the PBPK model. 60% of studies were within 2-fold, of which 40% were within 1.5-fold. A clinical DDI study where proguanil was the victim of a CYP2C19-mediated DDI was accurately recovered using the PBPK model.
Limitations	Prediction of cycloguanil exposure was complicated by not knowing the polymorphism classification of subjects in each study, hence the model performance was deemed acceptable using the criteria of being within 2-fold of observed. Verification needed for perpetrator DDI assessment as literature data is unavailable at this time
Updates in V19	Recalculated fm values using the corrected dose administered in Jeppesen et al., 1997 Previous version used paper calculation of total clearance which did not account for the weight of the salt in the 200 mg dose administered Model converted from minimal to full PBPK distribution model Updated in vitro data Updated CYP2D6 IC₅₀

Search Score: 2

Cancer_Population_V10R1_Genentech_20170113

Model Files Publication

The attached file is the cancer population file that was developed by Genentech in Simcyp V10 and published by Cheeti et al Biopharm. Drug Dispos. (2013).

Search Score: 2

Capmatinib_RES_V21R1_Simcyp_20230615

Model Files Publication

The RES-Capmatinib_V21 model has been developed primarily as an inhibitor of hepatic OATP1B1 and OATP1B3, and intestinal BCRP using the New GI physiology in Simcyp V21 with altered GI tract population inputs that became default for V22. The verification for 200mg SD, 400mg SD, 600mg SD is performed in the Sim-Healthy Volunteer population and for the 400 mg BID in the Sim-Cancer population. A multiple plasma protein approach is used, accounting for HSA, AGP, IgG and lipoprotein inputs for the populations. The metabolism is simulated using Cytosolic Oxidases (rhAO) and CYP3A4. The Rosuvastatin DDI is using a 400mg BID dosing for Capmatinib in the fasted state.

Search Score: 2

Search the PBPK Model Repository

Searching Tips

Cetirizine_V14R1_AstraZeneca_20200327

Cycloguanil

The model at-a-glance

Cancer_Population_V10R1_Genentech_20170113

Capmatinib_RES_V21R1_Simcyp_20230615

Your Privacy